HopeAI, a rising innovator in the application of artificial intelligence (AI) to speed up drug discovery and development, has joined the esteemed Mayo Clinic Platform Accelerate program. Through this collaboration, HopeAI gains access to Mayo Clinic’s exceptional real-world data (RWD) platform, a resource that can transform the way clinical trials are designed, making the process faster, more accurate, and more efficient.
One of the most difficult and costly processes in the medical field is the creation of a new medication. Worldwide, pharmaceutical companies collectively invest more than $300 billion annually in research and development, with the average drug taking around 12 years to progress from discovery to commercial availability. Clinical trials alone account for roughly 70% of both the cost and time involved, yet 90% of drug candidates never make it to patients.
This high failure rate has a significant effect. When late-stage trials collapse, potentially life-saving treatments for cancer, cardiovascular disease, and rare conditions can be set back by years, while also adding to the overall cost of future healthcare. By combining sophisticated AI algorithms and statistical modeling with reliable, real-world medical data, HopeAI aims to address this issue. This powerful combination allows researchers to design trials more efficiently, identify the most suitable patients with greater precision, and enhance the reliability of trial outcomes. The result is a greater likelihood that promising therapies will reach those who need them, faster and with improved success rates.
Being selected for Mayo Clinic’s Accelerate program reflects a high level of trust and validation, placing HopeAI among a select group of innovators who gain direct access to Mayo’s expertise and unparalleled data assets. A key innovation from HopeAI is its AI Agents, developed in partnership with HemOnc.org, the largest medical wiki focused on cancer care. This technology assists clinicians and trial designers by delivering evidence-based recommendations, pinpointing ideal patient groups, and minimizing trial delays.
Already working with two of the top ten global pharmaceutical companies and several forward-thinking biotech firms, HopeAI has demonstrated strong market interest and the potential for scalable commercial growth. This partnership signals a major step forward for the company, positioning it at the forefront of AI, big data, and precision medicine, with the mission of accelerating clinical development and improving patient outcomes worldwide.
